Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Non-Current Assets data on file, last reported at $910.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 3.73% year-over-year to $910.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 billion (up 1.97% YoY), and the FY2025 full-year result was $915.7 million, down 3.07% from the prior year.
• Non-Current Assets for Q1 2026 stood at $910.2 million, down from $915.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $945.6 million in Q1 2025 and bottomed at $835.8 million in Q1 2024.
• The 5-year median for Non-Current Assets is $854.1 million (2022), against an average of $875.9 million.
• The widest annual swing landed in 2024, when Non-Current Assets retreated 4.73%; it then gained 13.13% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $854.1 million in 2022, then decreased by 0.81% to $847.2 million in 2023, then grew by 11.51% to $944.7 million in 2024, then decreased by 3.07% to $915.7 million in 2025, then dropped by 0.59% to $910.2 million in 2026.
• The last three Non-Current Assets figures came in at $910.2 million (Q1 2026), $915.7 million (Q4 2025), and $898.9 million (Q3 2025), per Business Quant data.

Peer Comparison